Insulet stock carries RBC Buy rating as growth remains strong

Published on 10/04/2026 at 22:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insulet stock carries an RBC Buy rating with a USD 160.00 target dated October 1, 2026. Second-quarter adjusted EPS rose 41.5 percent to USD 1.66.

Makroaufnahme Insulet – weißer Insulin-Pod-Device mit Klebefolie und Kanüle auf blauem Bokeh — Insulet Medizintechnik-Makro: weißer schlauchfreier Insulin-Pod in extremer Nahaufnahme mit Klebefolie, ISIN US45784P1012, Illustration mit AI erstellt.

Insulet stock (ISIN US45784P1012) was last at USD 131.69 on Nasdaq on October 2, 2026, after a daily gain of 0.69 percent. Markets Insider reported that RBC Capital maintained a Buy rating and a USD 160.00 price target on October 1, 2026.

RBC target stays above Nasdaq price

The RBC target stands 21.5 percent above the October 2 price, a gap that reflects continued confidence in Insulet's Omnipod platform despite a sharp valuation reset during 2026. The stock's 52-week range is USD 126.40 to USD 354.88, placing the latest price USD 5.29 above the yearly low and USD 223.19 below the high.

Consensus remains more constructive on valuation than the latest rating label suggests. MarketBeat lists a Hold consensus from 26 analysts, an average target of USD 195.40, a high target of USD 375.00 and a low target of USD 144.00.

Q2 growth carried earnings higher

Insulet generated USD 801.7 million in second-quarter 2026 revenue, according to Zacks. Reported revenue increased 23.5 percent year over year, while adjusted EPS rose 41.5 percent to USD 1.66 from USD 1.17 in the second quarter of 2025.

The operating mix explains why the earnings growth exceeded the revenue increase. Adjusted gross margin reached 72.9 percent, up 3.2 percentage points year over year, and adjusted operating margin expanded 1.4 percentage points to 19.3 percent, according to Zacks.

Guidance puts utilization in focus

Insulet's 2026 constant-currency revenue growth outlook is 20 percent to 22 percent, while U.S. Omnipod growth is projected at 17 percent to 19 percent. The U.S. range was lowered from 20 percent to 22 percent, whereas international Omnipod growth was raised to 30 percent to 32 percent.

That split makes customer utilization and retention the central operating issue for the next report. International expansion is supplying a stronger growth rate, while the lower U.S. range sets a tougher benchmark for the domestic Omnipod business.

November results set the next test

StockTitan reported that Insulet will publish third-quarter 2026 results on November 4, 2026, before the market opens. Management also scheduled an earnings call for 8:00 a.m. ET that day.

Insulet's market capitalization is USD 9.1 billion as of October 2, 2026. The combination of 23.5 percent quarterly revenue growth, a 41.5 percent adjusted EPS increase and a 17 percent to 19 percent U.S. growth outlook gives the November report three measurable checkpoints.